Libya vs United States Virgin Islands: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Libya
0.2%
in 2024
United States Virgin Islands
0.2%
in 2024
Libya rank
78th
United States Virgin Islands rank
78th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Libya
- United States Virgin Islands
How they compare
Libya currently reports 0.2% against 0.2% in United States Virgin Islands, a difference of 0.0%.
Across all 10 years both countries report, United States Virgin Islands has been ahead every year.
Libya ranks 78th and United States Virgin Islands ranks 78th of 215 countries.
United States Virgin Islands has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Libya | United States Virgin Islands | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 0.3% | 0.1% | United States Virgin Islands |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Libya or United States Virgin Islands?
- Libya, at 0.2% against 0.2% in United States Virgin Islands as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Libya and United States Virgin Islands?
- 0.0%, with Libya ahead.
- How many years of comparable data are there for Libya and United States Virgin Islands?
- 10 years are reported by both, from 2015 to 2024.
- How do Libya and United States Virgin Islands rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Libya ranks 78th and United States Virgin Islands ranks 78th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.